#United States #San Diego #Shareholders #Johnson Fistel #Beta Bionics

Johnson Fistel Investigates Beta Bionics

In a significant development for investors, Johnson Fistel, PLLP announced on July 1, 2026, that it is conducting an investigation on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX). The inquiry is centered around potential violations of securities law that may have impacted investors due to misleading statements or omissions made by the company's executives regarding its performance and outlook.

Investigation Overview

The focus of the investigation stems from the alarming slowdown in new patient start growth reported by Beta Bionics for the fourth quarter of 2025. New patient starts are a critical performance indicator for the company, as they directly relate to Beta Bionics’ market presence and operational health. Following public disclosures about this deceleration, many investors expressed concerns over the reliability of the company's previous growth narratives.

On January 8, 2026, Beta Bionics revealed preliminary numbers for the fourth quarter, expecting approximately 5,581 new patient starts, which, while still indicating a 36% year-over-year growth, fell short of analysts’ forecasts. This stark deviation from anticipated growth rates—especially when compared to the 68% growth observed in the preceding quarter—has raised significant red flags.

Impact on Investors

The implications of these findings are profound, particularly for the shareholders who made investment decisions based on the company's optimistic outlook and prior performance claims. Investors who purchased securities of Beta Bionics and subsequently experienced losses are encouraged to evaluate their legal rights in light of these revelations. Johnson Fistel has urged such investors to join the ongoing investigation to explore their options, highlighting that participation carries no cost or obligation.

About Johnson Fistel

Johnson Fistel, PLLP is renowned as a leader in shareholder rights law, boasting a strong track record of advocating for both individual and institutional investors. The firm has multiple locations across the United States, including California, New York, and Georgia, reflecting its national presence in investor protection. With its accolades, including recognition as one of the top plaintiff law firms by ISS Securities Class Action Services, Johnson Fistel has a proven history of recovering substantial amounts for investors—approximately $90.7 million in 2024 alone.

For those impacted by the downturn in Beta Bionics' securities, or for anyone with concerns regarding their investments, Johnson Fistel provides a critical resource. Investors can reach out to James Baker at (619) 814-4471 or via email for more information.

In summary, as the investigation unfolds, it remains imperative for Beta Bionics shareholders to stay informed regarding the evolving situation. The health of the company and its transparency with investors will be pivotal not only for those directly affected but also for the overall reputation of Beta Bionics moving forward.

Further Steps for Investors

To stay involved or to seek further details about your rights as a shareholder in Beta Bionics, consider contacting Johnson Fistel. This could be your opportunity to address any financial grievances resulting from perceived mismanagement or lack of transparency by the organization. As such situations develop, staying proactive will be vital for affected investors.

Contact Information:

• - Phone: (619) 814-4471
• - Email: [email protected]
• - Address: 501 W. Broadway, Suite 800, San Diego, CA 92101